United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 45.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 8,288 shares of the biotechnology company’s stock after selling 6,815 shares during the quarter. Intech Investment Management LLC’s holdings in United Therapeutics were worth $2,970,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. ClariVest Asset Management LLC boosted its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new position in United Therapeutics during the second quarter worth $30,000. Innealta Capital LLC purchased a new position in shares of United Therapeutics during the second quarter worth $33,000. USA Financial Formulas acquired a new stake in shares of United Therapeutics in the third quarter valued at $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at $82,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on UTHR shares. The Goldman Sachs Group lifted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Argus lifted their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Stock Up 1.5 %

UTHR opened at $372.89 on Friday. The firm has a market cap of $16.65 billion, a price-to-earnings ratio of 16.38, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The business’s 50 day moving average is $365.06 and its two-hundred day moving average is $331.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period in the previous year, the business posted $5.38 earnings per share. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. Equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of United Therapeutics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares of the company’s stock, valued at approximately $1,108,766.10. The trade was a 70.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $1,034,510.88. This trade represents a 85.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 117,496 shares of company stock valued at $43,765,042 in the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.